School of Nursing, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Cardiology, The First Hospital of Jilin University, Changchun, China.
Front Endocrinol (Lausanne). 2021 Jun 25;12:598005. doi: 10.3389/fendo.2021.598005. eCollection 2021.
Diabetes mellitus (DM) is a highly prevalent chronic disease that is accompanied with serious complications, especially cardiac and vascular complications. Thus, there is an urgent need to identify new strategies to treat diabetic cardiac and vascular complications. Nuclear factor erythroid 2-related factor 2 (NRF2) has been verified as a crucial target for the prevention and treatment of diabetic complications. The function of NRF2 in the treatment of diabetic complications has been widely reported, but the role of NRF2-related epigenetic modifications remains unclear. The purpose of this review is to summarize the recent advances in targeting NRF2-related epigenetic modifications in the treatment of cardiac and vascular complications associated with DM. We also discuss agonists that could potentially regulate NRF2-associated epigenetic mechanisms. This review provides a better understanding of strategies to target NRF2 to protect against DM-related cardiac and vascular complications.
糖尿病(DM)是一种高发的慢性疾病,伴随着严重的并发症,尤其是心脏和血管并发症。因此,急需寻找新的策略来治疗糖尿病心脏和血管并发症。核因子红细胞 2 相关因子 2(NRF2)已被证实是预防和治疗糖尿病并发症的关键靶点。NRF2 在治疗糖尿病并发症中的作用已被广泛报道,但 NRF2 相关表观遗传修饰的作用尚不清楚。本综述的目的是总结针对 NRF2 相关表观遗传修饰在治疗与 DM 相关的心脏和血管并发症方面的最新进展。我们还讨论了可能调节 NRF2 相关表观遗传机制的激动剂。本综述为靶向 NRF2 以预防 DM 相关心脏和血管并发症的策略提供了更好的理解。